The primary objective of the current proposal is to develop new criteria which will identify patients in need of adjuvant therapy and differentiate these patients from those in whom surgical therapy alone is curative. Many oncologists rely on primary tumor depth and clinically detectable disease in their determination of applicable therapy. The management of melanoma can be improved if techniques to detect micrometastases are developed to augment those in current practice. During the last grant period we developed innovative lymphatic mapping and selective lymphadenectomy techniques (Project III). These techniques have allowed us to detect occult melanoma cells by intraoperative frozen sections in regional lymph nodes of clinical Stage I melanoma patients. This technique accurately identifies patients with early stage melanoma who have nodal metastases and are likely to benefit from radial lymphadenectomy. Furthermore, it avoids unnecessary lymph node dissection in those patients whose tumors failed to metastasize. This new approach will be extended to the multicenter cooperative study in the current year. On the other hand, a substantial number of Stage I melanoma patients with occult-node metastases do not benefit from lymphadenectomy since they die from their disseminated metastases. Furthermore, 20% of all patients without occult metastases detected by H&E staining and/or immunostaining recur within 5 years despite resection of their nodes. It is obvious that these patients have subclinical systemic metastases at the time of initial surgical treatment. Therefore, we propose to investigate methods to identify Stage I patients who may require adjuvant therapy. Various histological, immunological, and molecular/biochemical methods will be evaluated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA029605-16S1
Application #
2728857
Study Section
Special Emphasis Panel (SRC (1D))
Program Officer
Wu, Roy S
Project Start
1981-04-01
Project End
1998-05-31
Budget Start
1997-07-01
Budget End
1998-05-31
Support Year
16
Fiscal Year
1998
Total Cost
Indirect Cost
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Jones, Maris S; Lee, Jihey; Stern, Stacey L et al. (2017) Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes? J Am Coll Surg 225:149-158
Faries, Mark B; Thompson, John F; Cochran, Alistair J et al. (2017) Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376:2211-2222
Ozao-Choy, Junko; Nelson, Daniel W; Hiles, Jason et al. (2017) The prognostic importance of scalp location in primary head and neck melanoma. J Surg Oncol 116:337-343
Karakousis, Giorgos; Gimotty, Phyllis A; Bartlett, Edmund K et al. (2017) Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. Ann Surg Oncol 24:952-959
Jones, Maris S; Torisu-Itakura, Hitoe; Flaherty, Devin C et al. (2016) Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. Am Surg 82:1009-1013
Faries, Mark B (2016) Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology. Crit Rev Oncog 21:65-73
Ono, Shigeshi; Oyama, Takashi; Lam, Stella et al. (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6:7053-64
Wang, Jinhua; Huang, Sharon K; Marzese, Diego M et al. (2015) Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol 135:532-541
Cochran, Alistair J; Huang, Rong-Rong; Su, Albert et al. (2015) Is sentinel node susceptibility to metastases related to nodal immune modulation? Cancer J 21:39-46
Marzese, Diego M; Huang, Sharon K; Hoon, Dave S B (2015) In Situ Sodium Bisulfite Modification of Genomic DNA from Microdissected Melanoma Paraffin-Embedded Archival Tissues. Methods Mol Biol :

Showing the most recent 10 out of 256 publications